HC Wainwright Lowers Earnings Estimates for Opus Genetics

Opus Genetics, Inc. (NASDAQ:IRD) – Analysts at HC Wainwright reduced their Q1 2026 earnings estimates for shares of Opus Genetics in a note issued to investors on Wednesday, March 11th. HC Wainwright analyst M. Caufield now expects that the company will earn ($0.16) per share for the quarter, down from their previous estimate of ($0.09). The consensus estimate for Opus Genetics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Opus Genetics’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.64) EPS, FY2027 earnings at ($0.48) EPS, FY2028 earnings at ($0.20) EPS, FY2029 earnings at ($0.01) EPS and FY2030 earnings at $0.21 EPS.

IRD has been the subject of a number of other reports. Chardan Capital increased their price objective on Opus Genetics from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Thursday. Lifesci Capital upgraded Opus Genetics to a “strong-buy” rating in a research report on Thursday, February 12th. Wall Street Zen raised Opus Genetics from a “sell” rating to a “hold” rating in a research note on Sunday, March 1st. Brookline Capital Acquisition raised Opus Genetics to a “strong-buy” rating in a report on Monday, December 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Opus Genetics in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Opus Genetics presently has an average rating of “Buy” and a consensus target price of $9.25.

Opus Genetics Stock Performance

IRD opened at $5.03 on Friday. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 0.18. The business’s 50 day moving average is $3.19 and its 200-day moving average is $2.32. The stock has a market cap of $346.87 million, a PE ratio of -6.13 and a beta of 0.45. Opus Genetics has a twelve month low of $0.65 and a twelve month high of $5.30.

Institutional Trading of Opus Genetics

A number of large investors have recently added to or reduced their stakes in the business. Occudo Quantitative Strategies LP acquired a new position in Opus Genetics in the fourth quarter worth approximately $25,000. Virtu Financial LLC bought a new position in shares of Opus Genetics in the fourth quarter valued at $34,000. Johnson Investment Counsel Inc. acquired a new stake in shares of Opus Genetics during the 4th quarter valued at $40,000. Raymond James Financial Inc. boosted its stake in shares of Opus Genetics by 95.6% during the 3rd quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock worth $37,000 after acquiring an additional 11,000 shares in the last quarter. Finally, Blair William & Co. IL boosted its stake in shares of Opus Genetics by 12.3% during the 4th quarter. Blair William & Co. IL now owns 27,466 shares of the company’s stock worth $55,000 after acquiring an additional 3,000 shares in the last quarter. 14.97% of the stock is currently owned by institutional investors.

Insider Activity at Opus Genetics

In other Opus Genetics news, Director Cam Gallagher purchased 83,000 shares of the company’s stock in a transaction on Monday, December 29th. The shares were purchased at an average cost of $1.97 per share, for a total transaction of $163,510.00. Following the completion of the transaction, the director owned 83,000 shares in the company, valued at $163,510. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 6.60% of the company’s stock.

Key Stories Impacting Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Multiple firms raised price targets and reiterated positive ratings (supports upside momentum). Chardan raised its target to $11 with a Buy rating. Chardan price target raise
• Positive Sentiment: Wedbush boosted its target to $10 and kept an Outperform rating—another endorsement from a sell‑side shop. Wedbush price target raise
• Positive Sentiment: BTIG raised its price target to $12 (from $7) and maintained a Buy—adds to the cluster of higher targets that can drive investor interest. BTIG note
• Positive Sentiment: Clinical update: Opus provided progress on its Nyxol (oxymetazoline) clinical program (Phase 3 presbyopia/night‑vision studies), which is a near‑term catalyst investors watch for regulatory/market readthroughs. Clinical trial update
• Neutral Sentiment: H.C. Wainwright publicly remains constructive on Opus (keeps a Buy stance), which supports ongoing investor confidence even amid forecast changes. HC Wainwright buy rating
• Negative Sentiment: HC Wainwright cut near‑term EPS estimates across 2026 quarters and lowered FY2026 (to −$0.64) and FY2027/FY2028 forecasts substantially — this reflects a darker near‑term profitability outlook and could pressure the stock if clinical/operational progress stalls.
• Negative Sentiment: Lifesci Capital also trimmed Q1/Q2 and FY2026 EPS estimates (despite keeping a Strong‑Buy rating), signaling some analyst caution about timing or magnitude of revenue/cost assumptions.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.